Remove Bioavailability Remove Genotoxicity Remove Research Remove Trials
article thumbnail

The Composition and Value of a Portfolio Analysis

Camargo

Pediatric Research Equity Act (PREA) Requirements. This is a key factor in designing Phase 2 and 3 trials. Clinical pharmacology may also involve comparative bioavailability analyses, which are generally required for drug formulation bridging studies, to demonstrate bioequivalence. Clinical Pharmacology.

article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We Animals were administered molnupiravir for longer and at higher doses (mg/Kg) than those employed in human studies. About Molnupiravir.

Trials 69